Marc Voight, page-19

Hi Ahjay.
At least 11 since January after the first 6 safety cohort were discharged. This, from October report to share holders…
EAT COVID - Phase II
EAT COVID is an investigator-initiated Phase II clinical trial being conducted in the Czech Republic by the University Hospital Pilsen, which is the sponsor of the trial and has full control and responsibility for running and funding it. The study is evaluating efti in up to 110 hospitalised patients with COVID-19.
In January 2021, safety data reported by the University Hospital Pilsen from the first six patients were reviewed by an independent Data and Safety Monitoring Board. All six patients (age range, 50-83 years; 2 women and 4 men) received the three planned 10 mg efti injections and were since discharged from hospital with no adverse events reported.
The safety data prompted the Hospital to initiate enrolment for the randomised portion of the study which is ongoing.
The first cohort of the randomised stage has not been fully recruited yet. Currently 11/26 patients for this cohort have been recruited. While there were many COVID-19 cases in the Czech Republic earlier this year, the University Hospital Pilsen (which is the only site where recruitment for this trial is taking place) was overwhelmed and focused on the most severe cases. Now recruitment at this site has slowed due to declining COVID-19 patient numbers and increasing vaccination rates in the Czech Republic.
As the study is randomized and blinded we do not possess new data at this point in time, but will update the market as soon as we become aware of those from the investigator.

It’s not setting the world on fire for recruiting speed but news expected H1 2022. Maybe the appearance of Omicron will prompt some faster action on the trial and a surprise update before the end of the year.

The reality is we are going to need treatments particularly for the immune compromised. New variants will keep coming. I think EAT Covid trial is still a dark horse that could surprise. Triebel’s comments on Efti potential as a Covid treatment are very positive.